]>
IRCT20111206008307N36 IRCT 2020-07-28 Tabriz University of Medical Sciences Evaluation of the effect of Allopurinol in reducing heart damage in acute ischemic heart patients Evaluation of Allopurinol effect on Plasma Level of Cardiac Troponin-I and Creatine Kinase- MB in acute ischemic heart disease (ACS) 2019-11-22 anticipated 100 Complete https://irct.ir/trial/46989 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: The randomization was performed based on computer-generated random numbers list using online Graphpad randomizer software (https://www.graphpad.com/quickcalcs/randMenu/) and an allocation ratio of 1:1 in two intervention (group A) and control (Group B) with sample size n=100. After randomization 50 patients allocated in group A and the other 50 patients allocated in group B. 2-3 Acute cardiac ischemic patients. Intervention 1: Intervention group: After diagnosis of ischemic heart disease, patients receive 600 mg of allopurinol, product of Hakim Pharmaceutical factory, in two divided doses on the first day and then 300 mg of allopurinol daily for 4 days.Then the blood levels of cTnI and CK-MB are checked every 8 hours for 5 times by ELISA. Intervention 2: Control group: Patients receive routine treatment after the diagnosis of ischemic heart disease. Blood levels of the cTnI and CK-MB enzyme are checked every 8 hours for 5 times by ELISA. Yes - There is a plan to make this available What will be shared: All of the data of an article can be published after making patients unrecognized When: After publishing of article until 6 months after publishing of the results To whom: Data will be available to researchers working in academic and scientific institutions Conditions: Researchers that request data will be permitted only to doing analysis according to ethics for scientific aims Where to obtain: Applicants can receive data by sending an E-mail to address of tentezari@gmail.com and get response from Dr. Taher Entezari Maleki How to obtain: After contacting with corresponding author(Dr.Taher Entezari Maleki), data will be sent to Tabriz Shahid Madani hospital ethics committee and after receiving permission, data will be send to applicants Comments:
public Dr. Taher Entezari-maleki
Shahid Madani Center, Daneshghah Street,Tabriz
Tabriz Iran (Islamic Republic of) 5166614766 +98 41 1339 2593 tentezari@gmail.com Tabriz University of Medical Sciences scientific Dr.Taher Entezari-Maleki
Faculty of Pharmacy,Daneshghah Street,Tabriz
Tabriz Iran (Islamic Republic of) 5166614766 +98 41 3339 2593 tentezari@gmail.com Tabriz University of Medical Sciences Iran (Islamic Republic of) Patients diagnosed with acute ischemic heart syndrome Age 80-18 years Ability to understand and sign consent forms 18 years 80 years Both Serum creatinine above 2 milligram Per deciliter Acute myocardial infraction History of dialysis Cardiogenic shock I21.4 Non-ST elevation (NSTEMI) myocardial infarction Treatment - Drugs Treatment - Drugs Intervention group: After diagnosis of ischemic heart disease, patients receive 600 mg of allopurinol, product of Hakim Pharmaceutical factory, in two divided doses on the first day and then 300 mg of allopurinol daily for 4 days.Then the blood levels of cTnI and CK-MB are checked every 8 hours for 5 times by ELISA. Control group: Patients receive routine treatment after the diagnosis of ischemic heart disease. Blood levels of the cTnI and CK-MB enzyme are checked every 8 hours for 5 times by ELISA. Cardiac troponin I. Timepoint: Before, 8, 16, 24 and 32 hours after receiving allopurinol. Method of measurement: ELISA kits. Creatine Kinase-MB. Timepoint: Before, 8, 16, 24 and 32 hours after receiving allopurinol. Method of measurement: ELISA kite. Tabriz University of Medical Sciences Approved 2019-07-18 Ethics Committee of Tabriz University of Medical Sciences Reasearch and Technology Deputy, Tabriz University of Medical Science, Golgasht Street, Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)